Ocular Therapeutix Inc. (NASDAQ: OCUL) stock rose by 3.14% at last close however the OCUL stock price declines by 4.06% in the after-market. Ocular Therapeutix is a pharmaceutical business that uses its patented bioresorbable hydrogel-based formulation technique to research, test, and commercialize novel treatments for illnesses and disorders of the eye.
>> 7 Top Picks for the Post-Pandemic Economy <<
OCUL stock Current Update
Regeneron has canceled the option and licensing contract between Ocular Therapeutix and Regeneron. On August 5, 2021, the termination took effect.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
The partnership with Regeneron began in 2016 with the goal of developing and commercializing medicines that combine OCUL’s sustained-release hydrogel technology with Regeneron’s big molecule VEGF-targeting drugs to treat eye diseases. The Company and Regeneron have concentrated their efforts under a 2020 modification on the research and development of an elongated formulation of aflibercept to be administered to the suprachoroidal space for the therapy of retinal disorders.
Antony Mattessich, President and CEO of OCUL stock stated,
Although they are unhappy to see the partnership coming to an end, they are still thankful for the opportunity to engage with Regeneron with a chemical like aflibercept. Most significantly, they learnt a lot about how to combine monoclonal antibodies with their unique hydrogel and deliver them to the suprachoroidal region. This initiative has the potential to be a strategic driver for their business in the future.
OCUL stock’s Recent Development
Ocular Therapeutix has drugged the first patient in Phase 1 clinical study of OTX-TKI for the cure of wet age-related macular degeneration in the United States.
This study will look at the safety, acceptability, and biological efficacy of OTX-TKI as a therapy for wet AMD. The OTX-TKI clinical trial is being performed in the United States under an experimental IND (eIND) application at five different locations with a total of 20 randomized subjects:
- 15 subjects will be handled with a single OTX-TKI implant involving 600 g of axitinib in conjunction with an anti-VEGF induction injection.
- 5 subjects will be handled with a dose of aflibercept at eight-week intervals.